|Over a week ago|
Northland starts $7 Oncternal Therapeutics at Outperform with $21 target » 08:2702/2302/23/21
As previously reported,…
As previously reported, Northland analyst Carl Byrnes initiated coverage of Oncternal Therapeutics with an Outperform rating and $21 price target. The company, whose shares closed at $7.20 on February 22, is developing "first-in-class therapeutics using untapped biological pathways for hematologic and solid malignancies," Byrnes tells investors. The interim data reported at the ASH 2020 meeing in December for its lead candidate cirmtuzumab "were stunning," according to Byrnes, who notes that the company is advancing cirmtuzumab for mantle cell lymphoma, chronic lymphocytic leukemia and breast cancer while also accelerating its ROR1-targeting CAR-T program.
Oncternal Therapeutics initiated with an Outperform at Northland » 08:0302/2302/23/21
Northland analyst Carl…
Northland analyst Carl Byrnes initiated coverage of Oncternal Therapeutics with an Outperform rating and $21 price target.
Largest borrow rate increases among liquid names » 08:4502/1602/16/21
ONCT, NXTD, SAVA, IGC, EMAN, DTEA, OBSV, SNPR, TLRY, PSAC
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Oncternal Therapeutics (ONCT) 51.09% +18.45, NXT ID (NXTD) 53.63% +10.22, Cassava Sciences (SAVA) 10.75% +7.42, India Globalization Capital (IGC) 19.57% +6.13, eMagin (EMAN) 15.03% +5.99, Davids Tea (DTEA) 32.54% +5.62, ObsEva (OBSV) 10.07% +5.10, Tortoise Acquisition Corp II (SNPR) 10.99% +4.90, Tilray (TLRY) 19.82% +4.72, and (PSAC) 19.45% +4.65.
|Over a month ago|
Oncternal Therapeutics confirms agreement with Lentigen Technology » 08:2001/1401/14/21
Oncternal Therapeutics announced an agreement with Lentigen Technology, a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal's investigational ROR1-targeting CAR-T cell therapy program. As part of the agreement, Lentigen will reserve capacity in 2021 to manufacture, test and release GMP lentivirus to support and accelerate the development of Oncternal's CAR-T cell therapy program.
Oncternal, Karolinska Institutet in pact for ROR1-targeting cell therapy » 16:0901/0701/07/21
Oncternal Therapeutics announced that it established a research and development collaboration with world-renowned Karolinska Institutet in Stockholm, Sweden, to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK, Natural Killer, cells from the laboratory into the clinic. As part of the collaboration, IND-supporting preclinical studies will be performed in the Cell and Gene Therapy Group led by Evren Alici, M.D. Ph.D., within the NextGenNK Center, which is a Competence Center for the development of next-generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital as well as prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Sweden's innovation agency Vinnova, Karolinska Institutet, and the industrial partners. "Given that NK cells were discovered at Karolinska Institutet, we are excited to work together with industry partners to translate scientific advances into next-generation cell therapies that will benefit cancer patients," said Hans-Gustaf Ljunggren, M.D. Ph.D., Director of the NextGenNK competence center. "We look forward to collaborating with the outstanding team at Oncternal to develop cutting-edge T and NK cell therapies targeting ROR1, which is a promising target in many oncology indications. It could be ideally suited for cell therapy." "We are honored to work together with the world-leading academic team at Karolinska Institutet to accelerate the development of our ROR1-targeting CAR-T cell immunotherapy program," said James Breitmeyer, M.D., Ph.D., Oncternal's President and CEO. "ROR1 has emerged as an important and underexplored target for cancer therapy, and we believe that ROR1-targeting CAR-T and CAR-NK therapies hold significant promise for patients with both hematologic cancers and solid tumors. We believe that utilizing the ROR1 binding domain of our clinical-stage antibody cirmtuzumab as a component of the CAR has the potential to give us a safety and efficacy advantage."
Eight new option listings and one option delisting on December 16th » 08:3012/1612/16/20
ABNB, ALXO, BYSI, ONCT, PLG, PSTX, YSG, DNKN
New option listings for…
New option listings for December 16th include Airbnb Inc (Class A Stock) (ABNB), ALX Oncology Holdings Inc (ALXO), BeyondSpring (BYSI), CF Finance Acquisition Corporation II (Class A Stock) (CFII), Oncternal Therapeutics (ONCT), Platinum Group (PLG), Poseida Therapeutics Inc (PSTX), and Yatsen Holding Limited (Class A ADS) (YSG). Option delistings effective December 16th include Dunkin Brands Group Inc (DNKN).
Oncternal Therapeutics announces $40M bought deal offering » 18:1312/0912/09/20
Oncternal Therapeutics announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 8,888,889 shares of common stock of the company, at a price to the public of $4.50 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 14, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The company intends to use the net proceeds from this offering for general corporate purposes, including expenses related to the clinical and preclinical development of cirmtuzumab and TK216, preclinical development of its ROR1 CAR-T program, and for working capital.
|Over a quarter ago|
Oncternal Therapeutics presents interim phase 1/2 data update for cirmtuzumab » 08:2812/0712/07/20
Oncternal Therapeutics announced updated interim clinical data from the ongoing Phase 1/2 CIRLL clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma and chronic lymphocytic leukemia. The clinical trial is being partially funded by the California Institute for Regenerative Medicine. The data were presented at the American Society of Hematology 2020 Virtual Annual Meeting. Abstract Title: Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia from a Phase 1/2 Study. As of the data cut-off date of October 30, 2020, 15 patients with relapsed/refractory MCL enrolled in the dose-finding and dose-expansion cohorts of this clinical trial were evaluable for efficacy: The overall best objective response rate was 87%, improved over the 83% ORR reported at ASCO 2020. The complete response rate, determined by Cheson criteria, remains 57% for Part 1 of the study, and is 47% for Part 1 + Part 2, including the three patients from Part 2 who have shorter followup. One of the seven patients had a complete metabolic response as assessed by PET scan, with an indeterminate bone marrow biopsy on blinded review. All complete responses remained durable, ranging from 5-25 months as of the cutoff date, with no progressions reported after achieving a CR. Six patients achieved a partial response. In addition, two patients had stable disease, for a total best clinical benefit rate of 100%. Median progression-free survival was not reached, with the 95% confidence interval above 17.5 months, after a median follow-up of 12.1 months. Patients had received a median of two prior therapies before participating in this clinical trial, with 73% of patients with two or more prior lines of therapy. Four patients had received prior treatment with ibrutinib and all four achieved clinical responses in this clinical trial, with two CRs and two PRs. Fourteen of the 15 evaluable patients had high or intermediate MCL International Prognostic Index risk score at study entry. Historical data published for single-agent ibrutinib for 370 patients with r/r MCL, who had received a median of two prior therapies, reported an ORR of 66%, CR rate of 20%, PR rate of 46%, and median PFS of 12.8 months. As of the data cut-off date on October 30, 2020, 56 evaluable patients with CLL were enrolled in the dose-finding, dose-confirming and randomized cohorts of this clinical trial, 49 of whom were treated with the combination of cirmtuzumab and ibrutinib: Forty-five of the 49 patients achieved a clinical response, for an overall best objective response rate of 92%, including one patient who achieved a CR. In addition, four patients had stable disease, for a total clinical benefit rate of 100%. The median PFS was not reached for patients with treatment-naive CLL after a median follow-up of 16.6 months, and median PFS was 29.5 months for patients with r/r CLL after a median follow-up of 17.1 months/ The combination of cirmtuzumab plus ibrutinib has been well tolerated, with adverse events consistent with those reported for ibrutinib alone. There have been no dose-limiting toxicities and no serious adverse events attributed to cirmtuzumab alone.
Oncternal Therapeutics 7.258M share Spot Secondary priced at $3.10 » 05:5711/1811/18/20
The deal size was…
The deal size was increased to 7.258M shares of common stock from 6.45M shares of common stock. H.C. Wainwright acted as sole book running manager for the offering.
Oncternal Therapeutics announces $20M bought deal offering » 17:2911/1711/17/20
Oncternal Therapeutics announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,451,613 shares of common stock of the company, at a price to the public of $3.10 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 20, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The gross proceeds to Oncternal, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter's option to purchase additional common stock, are expected to be approximately $20M.